Search Results - subject:"clinical trial"

Learning personalized treatment strategies with predictive and prognostic covariates in adaptive clinical trials

Alban, Andres; Chick, Stephen E.; Zoumpoulis, Spyros I. - 2024 - Revised version of 2022/33/TOM/DSC

Persistent link: https://www.econbiz.de/10014550850

Special FDA designations for drug development : orphan, fast track, accelerated approval, priority review, and breakthrough therapy

Michaeli, Daniel; Michaeli, Christoph T.; Albers, Sebastian - In: The European journal of health economics 25 (2024) 6, pp. 979-997

Persistent link: https://www.econbiz.de/10014633366

Optimal enrollment in late-stage new drug development with learning of drug's efficacy for group-sequential clinical trials

Tian, Zhili; Hazen, Gordon B.; Li, Hong - In: Manufacturing & service operations management : M & SOM 25 (2023) 1, pp. 88-107

Persistent link: https://www.econbiz.de/10014299549

How can a joint European health technology assessment provide an "additional benefit" over the current standard of national assessments?

Julian, Elaine; Gianfrate, Fabrizio; de Sola-Morales, Oriol - In: Health Economics Review 12 (2022) 1, pp. 1-12

drivers in HTAs today (scale 1, low to 5, high) were clinical trial design (mean 4.45), right endpoints (mean 4.40), and size …

Persistent link: https://www.econbiz.de/10014489870

Shaping a research agenda to ensure a successful European health technology assessment: Insights generated during the inaugural convention of the European Access Academy

Julian, Elaine; Pavlovic, Mira; de Sola-Morales, Oriol; … - In: Health Economics Review 12 (2022) 1, pp. 1-15

Objectives: Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealing with remaining uncertainties as well as transparent...

Persistent link: https://www.econbiz.de/10014489950

How can a joint European health technology assessment provide an "additional benefit" over the current standard of national assessments?

Julian, Elaine; Gianfrate, Fabrizio; Sola-Morales, Oriol de - In: Health economics review 12 (2022) 1, pp. 1-12

drivers in HTAs today (scale 1, low to 5, high) were clinical trial design (mean 4.45), right endpoints (mean 4.40), and size …

Persistent link: https://www.econbiz.de/10013329416

A scoping review of statistical methods for trial-based economic evaluations : the current state of play

El Alili, Mohamed; Dongen, Johanna M. van; Esser, Jonas L. - In: Health economics 31 (2022) 12, pp. 2680-2699

Persistent link: https://www.econbiz.de/10013461861

Shaping a research agenda to ensure a successful European health technology assessment : insights generated during the inaugural convention of the European Access Academy

Julian, Elaine; Pavlovic, Mira; Sola-Morales, Oriol de; … - In: Health economics review 12 (2022) 1, pp. 1-15

Persistent link: https://www.econbiz.de/10013492801

Learning personalized treatment strategies with predictive and prognostic covariates in adaptive clinical trials

Alban, Andres; Chick, Stephen E.; Zoumpoulis, Spyros I. - 2022

Persistent link: https://www.econbiz.de/10013373076

Financially adaptive clinical trials via option pricing analysis

Chaudhuri, Shomesh E.; Lo, Andrew W. - In: Journal of econometrics 240 (2024) 2, pp. 1-11

Persistent link: https://www.econbiz.de/10015075136

1
2
3
4
5
6
7
8
9
10
Next
Last